



Company Profile

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.


RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Stock Performance

NASDAQ: RDHL.US ¹

Last Trade:	8.98
Trade Time:	3:59 PM ET Aug 18, 2017
Change:	0.21 ↑ (2.395%)
Volume	67,405



TASE: RDHL ¹

Last Trade:	310.00
Trade Time:	4:24 PM IT Aug 17, 2017
Change:	2.00 ↑ (0.649%)
Volume	346,243



Press Releases [\[View all \]](#)

Aug 17, 2017

[RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules](#)

Aug 10, 2017

[RedHill Biopharma Provides 2017 Semi-Annual Business Update](#)

Jul 31, 2017

[RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease](#)

Events [\[View all \]](#)

Sep 10–12, 2017

[Rodman & Renshaw 19th Annual Global Investment Conference](#)

Sep 25–27, 2017

[Cantor Fitzgerald Global Healthcare Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 23, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)

RedHill Biopharma Ltd

Investor Relations Department
21 Haarbaa St
Tel Aviv 64739
Israel

[Visit IR website](#)

[Sign-up for email alerts](#)

